All met the following criteria: stability during hemodialysis for at least 1 month and a requirement for intravenous low-molecular-weight iron dextran to maintain or establish adequate iron stores.

Intravenous iron dextran is widely used in hemodialysis patients receiving erythropoietin (EPO) therapy because of its significant convenience in clinical practice. However, the amount of iron ...